A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.

TitleA20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.
Publication TypeJournal Article
Year of Publication2011
AuthorsGiulino L, Mathew S, Ballon G, Chadburn A, Barouk S, Antonicelli G, Leoncini L, Liu YFang, Gogineni S, Tam W, Cesarman E
JournalBlood
Volume117
Issue18
Pagination4852-4
Date Published2011 May 05
ISSN1528-0020
KeywordsDNA Mutational Analysis, DNA-Binding Proteins, Epstein-Barr Virus Infections, Gene Deletion, Gene Silencing, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Intracellular Signaling Peptides and Proteins, Lymphoma, AIDS-Related, Mutation, NF-kappa B, Nuclear Proteins, Tumor Necrosis Factor alpha-Induced Protein 3, Viral Matrix Proteins
Abstract

A20, a negative regulator of NF-κB, has been implicated as a tumor suppressor gene in multiple types of B-cell lymphoma. AIDS-related lymphomas (ARLs) are high-grade B-cell lymphomas that are frequently associated with EBV infection. We examined a panel of ARLs for A20 alterations. FISH showed A20 deletion in 6 of 33 cases (18%). A20 mutations were found in 3 of 19 cases (16%), including 2 cases with deletions of the comple-mentary allele. Immunohistochemistry showed the absence of A20 protein in 7 of 55 samples (13%). In contrast to reports in Hodgkin lymphoma in which EBV infection and A20 alteration are mutually exclusive, A20 inactivation was observed in both EBV(+) and EBV(-) cases. The EBV latent membrane protein 1, which activates NF-κB, was not expressed in 12 of 13 cases with A20 loss. In ARLs loss of A20 may be an alternative mechanism of NF-κB activation in the absence of latent membrane protein 1 expression.

DOI10.1182/blood-2010-10-310995
Alternate JournalBlood
PubMed ID21406721
PubMed Central IDPMC3100694
Grant ListR01 CA068939 / CA / NCI NIH HHS / United States
U01 CA121947 / CA / NCI NIH HHS / United States
UO1 CA121947 / CA / NCI NIH HHS / United States